FDA Expands ANKTIVA Approval to Cover Papillary and CIS Bladder Cancer

The FDA expanded ANKTIVA’s approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and carcinoma in situ (CIS) disease.